Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep 16;9(9):2995.
doi: 10.3390/jcm9092995.

Effect of Statin Use on the Clinical Manifestations, Laboratory Test Results and Outcome of Lyme Neuroborreliosis

Katarina Ogrinc  1 , Andrej Kastrin  2 , Stanka Lotrič-Furlan  1 , Petra Bogovič  1 , Tereza Rojko  1 , Tjaša Cerar-Kišek  3 , Eva Ružić-Sabljić  3 , Gary P Wormser  4 , Franc Strle  1
Affiliations

Effect of Statin Use on the Clinical Manifestations, Laboratory Test Results and Outcome of Lyme Neuroborreliosis

Katarina Ogrinc et al. J Clin Med. .

Abstract

Statins have anti-inflammatory and potentially antimicrobial activity, but whether they have a beneficial effect on the course of infectious diseases is controversial. In this study, we assessed the impact of pre-existing statin use on the course and outcome of Lyme neuroborreliosis manifested as meningoradiculitis (Bannwarth's syndrome). One hundred and twenty three consecutive patients with Bannwarth's syndrome, of whom 18 (14.6%) were being treated with statins, were included in the study. To assess the influence of statin use on the course and outcome of the disease, univariate and multivariable analyses were performed. No statistically significant association was found between statin pre-treatment and the clinical manifestations, laboratory test results, and outcome of Bannwarth's syndrome. In conclusion, pre-existing use of statins did not significantly impact either the clinical presentation or the outcome of Bannwarth's syndrome.

Keywords: Bannwarth’s syndrome; Lyme neuroborrelisis; course; outcome; statin.

PubMed Disclaimer

Conflict of interest statement

Gary P. Wormser reports receiving research grants from Immunetics, Inc., Institute for Systems Biology, Rarecyte, Inc., and Quidel Corporation. He owns equity in Abbott/AbbVie; has been an expert witness in malpractice cases involving Lyme disease; and is an unpaid board member of the American Lyme Disease Foundation. Franc Strle served on the scientific advisory board for Roche on Lyme disease serological diagnostics, received research support from the Slovenian Research Agency (grant numbers P3-0296, J3-1744 and J3-8195), and is an unpaid member of the steering committee of the ESCMID Study Group on Lyme Borreliosis/ ESGBOR. All other authors have declared no potential conflicts of interest.

Similar articles

See all similar articles

Cited by

References

    1. Stanek G., Wormser G.P., Gray J., Strle F. Lyme borreliosis. Lancet. 2012;379:461–473. doi: 10.1016/S0140-6736(11)60103-7. - DOI - PubMed
    1. Pfister H.W., Kristoferitsch W., Meier C. Early neurological involvement (Bannwarth’s syndrome) In: Weber K., Burgdorfer W., editors. Aspects of Lyme Borreliosis. Springer; Berlin, Germany: 1993. pp. 152–167.
    1. Ogrinc K., Lusa L., Lotrič-Furlan S., Bogovič P., Stupica D., Cerar T., Ružić-Sabljić E., Strle F. Course and outcome of early European Lyme neuroborreliosis (Bannwarth syndrome): Clinical and laboratory findings. Clin. Infect. Dis. 2016;63:346–353. doi: 10.1093/cid/ciw299. - DOI - PubMed
    1. Potena L., Frascaroli G., Grigioni F., Lazzarotto T., Magnani G., Tomasi L., Coccolo F., Gabrielli L., Magelli C., Landini M.P., et al. Hydroxymethyl-glutaryl co-enzyme A reductase inhibition limits cytomegalovirus infection in human endothelial cells. Circulation. 2004;109:532–536. doi: 10.1161/01.cir.0000109485.79183.81. - DOI - PubMed
    1. del Real G., Jimenez-Baranda S., Mira E., Lacalle R.A., Lucas P., Gómez-Moutón C., Alegret M., Peña J.M., Rodríguez-Zapata M., Alvarez-Mon M., et al. Statins inhibit HIV-1 infection by down-regulating rho activity. J. Exp. Med. 2004;200:541–547. doi: 10.1084/jem.20040061. - DOI - PMC - PubMed

LinkOut - more resources